XJPX
5592
Market cap164mUSD
Jul 10, Last price
2,409.00JPY
1D
-0.70%
1Q
-8.85%
IPO
27.12%
Name
Kusurinomadoguchi Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its comprehensive platform includes patient-facing services such as the EPARK drug counter, an online portal for locating and booking appointments at pharmacies, and the EPARK medicine notebook, which enables digital management of family prescriptions and reservation for medication dispensations. The company also offers a dedicated site facilitating telephone medical consultations for over-the-counter medicines, alongside a system allowing patients to select their preferred pharmacy for services, and provides online medication guidance as well as hospital-supported online consultations. For pharmacy operations and management, Kusurinomadoguchi delivers Health Tech Navi, an electronic medication history system, and the Care Daisy system, which integrates various recording tools and ICT devices. It further provides procurement solutions for pharmaceuticals, including a marketplace for dispensing pharmacies to efficiently buy and sell surplus or slow-moving inventory, extending to the management and acquisition of otherwise stagnant stock. The firm also features a centralized management system to streamline outpatient reception, appointment scheduling, and online medical treatments. Additionally, it offers Pharmacy Support, a robust customer relationship management (CRM) system tailored for engaging repeat patients, alongside specialized operational systems for dispensing pharmacies and a matching service connecting nursing care facilities with appropriate pharmacies.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||